⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315059 | 0.88 | L3MBTL1 (0.43) | — | |
| SCHEMBL534479 | 0.86 | L3MBTL1 (0.50) | — | |
| SCHEMBL533685 | 0.84 | TDP1 (0.49) | — | |
| SCHEMBL1335859 | 0.84 | TDP1 (0.49) | — | |
| SCHEMBL5749901 | 0.84 | TDP1 (0.49) | — | |
| SCHEMBL213916 | 0.82 | — | — | |
| SCHEMBL11552400 | 0.78 | — | — | |
| SCHEMBL7367240 | 0.78 | ALDH1A1 (0.35) | — | |
| SCHEMBL9225030 | 0.75 | — | — | |
| SCHEMBL8633968 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| CN-109970708-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4631339-A | 1,3,5-triazepinones | ELI LILLY AND COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4514564-A | 7β-(2'-(1\",3\",5\"-Triazepin-4\"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4436912-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4430499-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-07 | — | — | US | disclosed |